贝达药业：BPB-101项目因综合优势不明显已暂停开发

Core Viewpoint - Betta Pharmaceuticals is advancing its dual-target antibody MCLA-129, which targets EGFR and c-Met, in the lung cancer field, with a recent Phase II study focusing on patients with positive driver genes and MET amplification [2] Group 1 - MCLA-129 is a bispecific antibody currently exploring indications in lung cancer [2] - The Phase II study related to driver gene positive and MET amplification has completed the enrollment of its first patient [2] - The company will disclose significant research progress in a timely manner [2] Group 2 - The BPB-101 project has been suspended due to its lack of comprehensive advantages [2]